Evaluation of Efficacy and Safety of Etanercept Therapy in Patients with Early and Late Juvenile Idiopathic Arthritis without Systemic Manifestations

Background: An issue related to the terms of assignment of genetically engineered biological agents to patients with juvenile idiopathic arthritis (JIA) still remains debatable in pediatric rheumatology.

Objective: Our aim was to evaluate the efficacy and safety of etanercept therapy in early and late JIA without systemic manifestations.

Methods: An observational comparative study. The participants were divided into 2 groups. Patients of the treatment group (n = 98) — with early arthritis (lasting less than 2 years), and patients of the control group (n = 99) — with late arthritis (lasting more than 2 years). All children received etanercept in a dose of 0.4 mg/kg body
weight 2 times per week subcutaneously. The efficacy of the therapy was evaluated for 3 years using the criteria of the American College of Rheumatology (ACRрedi), remission criteria by C. Wallace and JADAS71 index. Results: Total number of patients with JIA under the study is 197. After 6 months, the improvement according to the ACRpedi criteria 30/50/70 was recorded in 97/97/91% and 98/96/88%, and after 1 year — in 100/100/99% and 99/94/92% of patients with early and late arthritis, respectively. The efficacy of etanercept according to criteria by C. Wallace and JADAS71 index in early arthritis was higher than in late arthritis within 2 years of observation.

Conclusion: Etanercept is more effective in early JIA than in late JIA without systemic manifestations.

1. Harris J. G., Kessler E. A., Verbsky J. W. Update on the Treatment of Juvenile Idiopathic Arthritis. Curr. Allergy Asthma Rep. 2013; 13 (4): 337–346.

2. Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J. et al. International League of Associations for Rheumatology classifications of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31: 390–392.

3. Brewer E. J., Bass J., Baum J., Cassidy J. T., Fink C., Jacobs J. et al. Current proposed revision of JRA criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Com mittee of the American Rheumatism Section of the Arthritis Foundation. Arthritis Rheum. 1977; 20 (Suppl.): 195–199.

4. Petty R. E., Southwood T. R., Baum J., Bhettay E., Glass D. N., Manners P. et al. Revision of the proposed criteria for juvenile idiopathic arthritis: Durban 1997. J. Rheumatol. 1998; 25: 1991–1994.

5. Woo P., Wedderburn L. R. Juvenile chronic arthritis. Lancet. 1998; 351: 969–973.

6. Каратеев Д. Е., Лучихина Е. Л., Муравьев Ю. В., Н. В. Демидова, Гринева Г. И., Новикова Д. С. и др. Первое Российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013; 2: 117–125.

7. Anderson J. J., Wells G., Verhoeven A. C., Felson D. T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000; 43: 22–29.

8. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis [editorial]. Arthritis Rheum. 2003; 48: 1771–1774.

9. Moreland L. W., Bridges S. L., Jr. Early rheumatoid arthritis: a medical emergency? Am. J. Med. 2001; 111: 498–500.

10. Mottonen T., Hannonen P., Korpela M., Nissila M., Kautiainen H., Ilonen J. et al. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002; 46: 894–898.

11. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hobooken). 2011; 63 (4): 465–482.

12. Лукина Г. В., Сигидин Я. А., Насонов Е. Л. Применение инфликсимаба у больных ревматоидным артритом в клинической практике (по данным Российского регистра). Терапевтический архив. 2009; 8: 1–5.

13. Лукина Г. В., Сигидин Я. А., Позднякова Е. С. Инфликсимаб в российской клинической практике. Современная ревматология. 2012; 3: 37–44.

14. Лукина Г. В., Сигидин Я. А., Чичасова Н. В. Применение моноклональных антител к фактору некроза опухоли (ремикейд) при ревматоидном артрите: предварительные результаты. Терапевти ческий архив. 2003; 5: 9–12.

15. Tynjala P., Vahasolo P., Tarkiainen M., Kroger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicenter randomized open-label clinical trial. Ann. Rheum. Dis. 2011; 70 (9): 1605–1612.

16. Wallace C. A., Giannini E. H., Spalding S. J., Hashkes P. J., O’Neil K. M., Zeft A. S., Szer I. S., Ringold S., Brunner H. I., Schanberg L. E., Sundel R. P., Milojevic D., Punaro M. G., Chira P., Gottlieb B. S., Higgins G. C., Ilowite N. T., Kimura Y., Hamilton S., Johnson A., Huang B., Lovell D. J. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012; 64 (6): 2012–2021.

17. Albers H. M., Brinkman D. M., Kamphuis S. S., van Suijlekom-Smit L. W., van Rossum M. A., Hoppenreijs E. P. et al. Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken). 2010; 62: 204–212.

18. Wallace C. A., Huang B., Bandeira M., Ravelli A., Giannini E. H. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 3554–3562.

19. Алексеева Е. И., Слепцова Т. В., Валиева С. И., Бзарова Т. М., Денисова Р. В., Лисицин А. О., Исаева К. Б., Митенко Е. В., Чомахид зе А. М., Григорьева А. А., Ломакина О. Л. Эффективность и безопасность инфликсимаба у больных ранним и поздним ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2010; 9 (3): 30–42.

20. O’Dell J. R. Treating rheumatoid arthritis early: a window of opportunity? [editorial]. Arthritis Rheum. 2002; 46: 283–285.